SUCCESSFUL TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN

Google Scholar
  • 19 September 1987
    • journal article
    • research article
    • Vol. 117  (38) , 1397-1402
Abstract
Recombinant human erythropoietin (r-huEpo) was administered i.v. to eight anemic patients on hemodialysis in increaseing doses 3 times a week. 7 out of 8 patients showed an increase in hemoglobin level by 2 g/dl over the baseline of 7.9 .+-. 0.8 g/dl after a mean period of 8 .+-. 2 weeks. Durign treatment a cumulative dose of 692 .+-. 358 IU/kgBW erythropoietin was given. Before the rise in hemoglobin, reticulocytes increased from 1.6 .+-. 0.7% initially to 5 .+-. 1.6%. The serum ferritin concentration decreased from 426 (range 19-1223) to 250 (5-7070 .mu.g/l. No side effects were observed. Mean blood pressure before dialysis increased slightly from 125 mmHg to 137 mmHg systolic, and diastolic pressure from 75 to 80 mmHg. Maintenance doses to maintain hemoglobin values between 10 und 12 g/dl varied from 2 .times. 72 IU/kgBW to 3 .times. 168 IU/kgBW per week. Measurement of serum levels of erythropoietin by radioimmunoassay showed deficiency of the hormone in the patients with chronic renal failure: before treatment mean serum values were 4 .+-. 6.4 mU/ml and during maintenance doses with r-huEpo 33.7 .+-. 8.1 mU/ml, which is within normal ranges related to hematocrit. These data show erythropoietin to be effective in ameliorating anemia during hemodialysis treatment.